Antithrombin-lowering in hemophilia: a closer look at fitusiran

Bleeding episodes significantly reduced in study of hemophilia drug

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect

Hemostatic disorders and hereditary angioedema

siRNA against anti-thrombin reduces bleeding in hemophilia

Gene therapy in haemophilia: literature review and regional perspectives for Turkey - Kaan Kavaklı, Bülent Antmen, Vahap Okan, Fahri Şahin, Selin Aytaç, Can Balkan, Ergül Berber, Zühre Kaya, Alphan Küpesiz, Bülent Zülfikar

Summer 2022 haemophilia trial update - European Pharmaceutical Review

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy

A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC

Fitusiran prophylaxis reduced bleeds by 61% in people with Hem A or B - Hemophilia Federation of America

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet

Summer 2022 haemophilia trial update - European Pharmaceutical Review

Full article: Current and emerging biologics for the treatment of hemophilia

Hemophilia therapy: the future has begun